8-K: Integer Holdings Completes CEO Transition, Appoints Khales

Integer Holdings Corporation announced the completion of its planned CEO transition, with Payman Khales succeeding Joseph W. Dziedzic and joining the Board of Directors.

Summary

• Integer Holdings Corporation completed its planned CEO transition, with Payman Khales assuming the role of President and Chief Executive Officer, effective October 24, 2025.
• Mr. Khales was also appointed as a member of the Board of Directors, effective October 24, 2025, and will serve on the Company's Technology Strategy Committee.
• He succeeds Joseph W. Dziedzic, who retired as CEO and director but will serve as a Special Advisor until March 31, 2026, to assist with transition matters.
• Mr. Khales's new compensation package includes an annual base salary of $875,000, a target annual short-term incentive bonus of 100% of his base salary, and a 2026 long-term incentive award target of not less than $5,000,000.
• He also received a special equity grant of service-based restricted stock units with a grant date fair value of $550,000, vesting ratably over three years from October 24, 2025.
• The Employment Agreement supersedes previous agreements from February 2018 and outlines severance compensation for both non-change in control and change in control scenarios, including cash severance, medical benefits, and accelerated equity vesting under specific conditions.
• The Company issued a press release on October 24, 2025, announcing the completion of the CEO transition plan.

Sentiment

Score: 8

Explanation: The filing details a smooth, planned leadership transition with a highly experienced internal candidate, Payman Khales, taking over as CEO. The outgoing CEO, Joseph W. Dziedzic, will remain as an advisor for a transition period, indicating continuity and stability, which is generally positive for corporate governance and investor confidence.

Positives

• The CEO transition was planned and executed smoothly, ensuring leadership continuity.
• Payman Khales has a strong internal track record, having doubled sales in the Cardio & Vascular business over seven years and driven above-market growth as President of that unit.
• Mr. Khales's recent role as Chief Operating Officer, overseeing both business units and global operations, provides comprehensive experience for the CEO position.
• Outgoing CEO Joseph W. Dziedzic will remain as a Special Advisor until March 31, 2026, facilitating a seamless handover.
• Mr. Khales's appointment to the Board of Directors and the Technology Strategy Committee aligns his leadership with strategic oversight.

Future Outlook

Payman Khales expressed enthusiasm for the opportunities ahead, stating a commitment to advancing the company's strategy, innovating, collaborating with customers, and delivering life-changing medical technologies to patients worldwide.

Management Comments

• "It is a privilege to step into the role of CEO at Integer. I am energized by the opportunities ahead as we continue to advance our strategy. Together with our talented associates, we will create value by innovating, collaborating with our customers, and delivering life-changing medical technologies to patients around the world. I am grateful to Joe for his mentorship and support, and I look forward to leading Integer."

Industry Context

Integer Holdings Corporation is a leading global medical device contract development and manufacturing organization (CDMO), serving critical markets such as cardiac rhythm management, neuromodulation, and cardio and vascular. The company positions itself as a strategic partner to medical device companies and OEMs, focusing on innovative, high-quality products and solutions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from a planned and smooth leadership transition, reducing uncertainty and signaling stability. The appointment of an internal candidate with a strong track record may instill confidence.
• Employees: May experience continuity and stability under new leadership, particularly with the outgoing CEO assisting in the transition.
• Customers and Suppliers: Can expect continued strategic partnership and operational focus, given the new CEO's background in operations and business unit leadership.

Next Steps

• Joseph W. Dziedzic will serve as a Special Advisor for the Company until March 31, 2026, to assist Mr. Khales with transition matters.
• Mr. Khales's term as director will continue until the next annual meeting of stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.

Key Dates

Recommendation

The filing details a planned and smooth CEO transition, which is generally a positive for corporate stability and governance. Payman Khales, an internal candidate with a strong track record, is taking the helm, and the outgoing CEO will assist in the transition. While this news is favorable for leadership continuity, it does not contain new financial performance data or significant strategic shifts that would immediately warrant a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and monitor future financial reports and strategic announcements under the new leadership for further investment decisions.

Keywords

Integer Holdings, ITGR, CEO transition, Payman Khales, Joseph Dziedzic, medical device, CDMO, corporate governance, executive compensation, Board of Directors, leadership succession